About Optivia Medical
Optivia Medical is a Winston-Salem, NC biotech company founded in 2004 that develops and commercializes patented products for use in endoscopic medicine. The first product, a hysteroscope with an introducer, steerable working channel, and visually guided dilator has reached the final stage of prototype production.
Optivia Medical Frequently Asked Questions (FAQ)
When was Optivia Medical founded?
Optivia Medical was founded in 2004.
Where is Optivia Medical's headquarters?
Optivia Medical's headquarters is located at 101 N. Chestnut Street, Winston-Salem.
What is Optivia Medical's latest funding round?
Optivia Medical's latest funding round is Unattributed.
How much did Optivia Medical raise?
Optivia Medical raised a total of $1.2M.
Who are the investors of Optivia Medical?
Investors of Optivia Medical include Piedmont Angel Network, IMAF-Triad and Jefferson Corner Group.
Who are Optivia Medical's competitors?
Competitors of Optivia Medical include Numares, OcuNexus Therapeutics, Helomics, ChanTest, GlobeImmune and 7 more.
Compare Optivia Medical to Competitors
CoImmune, fka Argos Therapeutics, is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. Using biological components from each patient, the company's immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease.
PNP Therapeutics is dedicated to the development and commercialization of a cancer treatment approach that is predicated on well-documented evidence that solid tumors can be compelled to develop their own chemotherapy and thus elicit their own self-destruction.
Radio Therapeutics Corporation develops and manufactures radiofrequency-based therapeutic devices for the destruction of various forms of soft tissue tumors. RTC markets the Radiofrequency Ablation System, which uses radiofrequency energy to selectively destroy undesirable soft tissue. The technology is based on hyperthermia (overheating) of the tumor to destroy it with the use of a specially designed probe which is inserted into the tumor. The probe architecture is the core of the technology and permits a localized application of radio-frequency energy. The system is used by radiologists and surgical oncologists for the ablation of nonresectable (inoperable) liver lesions.
Anza Therapeutics is developing active immunotherapies for the treatment of infectious diseases and cancer. Anza's therapeutic agents are based on its proprietary live-attenuated and Killed But Metabolically Active (KBMA) Listeria platforms which can be engineered to express antigens specific to the disease being treated.
CytImmune Sciences is a clinical stage nanomedicine company with a core focus on the discovery, development and commercialization of multifunctional, tumor-targeted therapies.
Isolating diverse creatures including species indegenous to rainforests in Malaysia, exploring new compounds which lead development of new medicine conforming to CBD and building a predominant bio-resource collection, NGS will contribute to health and progress of bioindustries in international community.